Calcified Tissue International

, Volume 82, Issue 5, pp 361–372 | Cite as

Soluble RANKL Induces High Bone Turnover and Decreases Bone Volume, Density, and Strength in Mice

  • S. A. J. Lloyd
  • Y. Y. Yuan
  • P. J. Kostenuik
  • M. S. Ominsky
  • A. G. Lau
  • S. Morony
  • M. Stolina
  • F. J. Asuncion
  • Ted A. Bateman


Receptor activator for nuclear factor-κ B ligand (RANKL) is an essential mediator of osteoclastogenesis. We hypothesized that administration of soluble RANKL to mice would result in high turnover and deleterious effects on both cortical and trabecular bone. For 10 days, 10-week-old C57BL/6J female mice (n = 12/group) were given twice-daily subcutaneous injections of human recombinant RANKL (0.4 or 2 mg/kg/day) or inert vehicle (VEH). Bone turnover was greatly accelerated by RANKL, as evidenced by the 49–84% greater levels of serum TRAP-5b (bone resorption marker) and 300–400% greater levels of serum alkaline phosphatase (bone formation marker). RANKL resulted in significantly greater endocortical bone erosion surface (79–83%) and periosteal bone formation rate (64–87%) vs. VEH. Microcomputed tomographic (microCT) analysis of the proximal tibia indicated a reduction in trabecular volume fraction (–84%) for both doses of RANKL. Cortical bone geometry and strength were also negatively influenced by RANKL. MicroCT analysis of the femoral diaphysis indicated significantly lower cortical bone volume (−10% to –13%) and greater cortical porosity (8–9%) relative to VEH. Biomechanical testing of the femur diaphysis revealed significantly lower maximum bending load (−19% to –25%) vs. VEH. Bone strength remained correlated with bone mass, independent of RANKL stimulation of bone turnover. These findings are consistent with the hypothesis that soluble RANKL could be an important etiologic factor in pathologic bone loss. RANKL also has potential utility as a model for studying the consequences of high bone turnover on bone quality and strength in animals.


RANKL Bone strength Turnover Microcomputed tomography Osteoporosis 



This work was supported by the National Space Biomedical Research Institute through NASA NCC 9–58, Amgen, Inc., and BioServe Space Technologies (through NASA NCC8–242). The editorial and formatting assistance of Jenny Bourne is greatly appreciated. Thanks also to Steven Adamu (Amgen, Inc.) for assistance in measuring biochemical markers and Michael Lemus for help with microCT analysis.


  1. 1.
    Ammann P, Rizzoli R (2003) Bone strength and its determinants. Osteoporos Int 14(Suppl 3):S13–S18PubMedGoogle Scholar
  2. 2.
    Heaney RP (2003) Is the paradigm shifting? Bone 33:457–465PubMedCrossRefGoogle Scholar
  3. 3.
    Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176PubMedCrossRefGoogle Scholar
  4. 4.
    Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319PubMedCrossRefGoogle Scholar
  5. 5.
    Khosla S (2001) The OPG/RANKL/RANK system. Endocrinology 142:5050–5055PubMedCrossRefGoogle Scholar
  6. 6.
    Hofbauer LC, Heufelder AE (2001) Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 79:243–253PubMedCrossRefGoogle Scholar
  7. 7.
    Turner CH (2002) Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 13:97–104PubMedCrossRefGoogle Scholar
  8. 8.
    Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ (2000) Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 157:435–448PubMedGoogle Scholar
  9. 9.
    Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345–357PubMedCrossRefGoogle Scholar
  10. 10.
    Takahashi N, Udagawa N, Suda T (1999) A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 256:449–455PubMedCrossRefGoogle Scholar
  11. 11.
    Kostenuik PJ, Shalhoub V (2001) Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 7:613–635PubMedCrossRefGoogle Scholar
  12. 12.
    Mizuno A, Kanno T, Hoshi M, Shibata O, Yano K, Fujise N, Kinosaki M, Yamaguchi K, Tsuda E, Murakami A, Yasuda H, Higashio K (2002) Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. J Bone Miner Metab 20:337–344PubMedCrossRefGoogle Scholar
  13. 13.
    Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597–3602PubMedCrossRefGoogle Scholar
  14. 14.
    Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, Sakai H (2000) Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 275:768–775PubMedCrossRefGoogle Scholar
  15. 15.
    Stolina M, Adamu S, Ominsky M, Dwyer D, Asuncion F, Geng Z, Middleton S, Brown H, Pretorius J, Schett G, Bolon B, Feige U, Zack D, Kostenuik PJ (2005) RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res 20:1756–1765PubMedCrossRefGoogle Scholar
  16. 16.
    Geusens PP, Landewe RB, Garnero P, Chen D, Dunstan CR, Lems WF, Stinissen P, van der Heijde DM, van der Linden S, Boers M (2006) The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 54:1772–1777PubMedCrossRefGoogle Scholar
  17. 17.
    Kim HR, Kim HY, Lee SH (2006) Elevated serum levels of soluble receptor activator of nuclear factor-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology (Oxford) 45:1197–1200CrossRefGoogle Scholar
  18. 18.
    Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL (2003) Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111:1221–1230PubMedGoogle Scholar
  19. 19.
    Ominsky MS, Li X, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Geng Z, Grisanti M, Tan HL, Corbin T, McCabe J, Simonet WS, Ke HZ, Kostenuik PJ (2008) RANKL inhibition with osteoprotegerin (OPG) increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J Bone Miner Res 23(5):672–682Google Scholar
  20. 20.
    McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–831PubMedCrossRefGoogle Scholar
  21. 21.
    Samadfam R, Xia Q, Goltzman D (2007) Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. J Bone Miner Res 22:55–63PubMedCrossRefGoogle Scholar
  22. 22.
    Yuan YY, Kostenuik PJ, Ominsky MS, Morony S, Adamu S, Simionescu DT, Basalyga DM, Asuncion FJ, Bateman TA (2008) Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease. Osteoporos Int 19(5):625–635PubMedCrossRefGoogle Scholar
  23. 23.
    Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260–1268PubMedCrossRefGoogle Scholar
  24. 24.
    Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H (1998) Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247:610–615PubMedCrossRefGoogle Scholar
  25. 25.
    Ruegsegger P, Koller B, Muller R (1996) A microtomographic system for the nondestructive evaluation of bone architecture. Calcif Tissue Int 58:24–29PubMedCrossRefGoogle Scholar
  26. 26.
    Dufresne T (1998) Segmentation techniques for analysis of bone by three-dimensional computed tomographic imaging. Technol Health Care 6:351–359PubMedGoogle Scholar
  27. 27.
    Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610PubMedCrossRefGoogle Scholar
  28. 28.
    Broz JJ, Simske SJ, Greenberg AR, Luttges MW (1993) Effects of rehydration state on the flexural properties of whole mouse long bones. J Biomech Eng 115:447–449PubMedCrossRefGoogle Scholar
  29. 29.
    Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586–1592PubMedCrossRefGoogle Scholar
  30. 30.
    Jiang Y, Zhao J, Genant HK, Dequeker J, Geusens P (1997) Long-term changes in bone mineral and biomechanical properties of vertebrae and femur in aging, dietary calcium restricted, and/or estrogen-deprived/-replaced rats. J Bone Miner Res 12:820–831PubMedCrossRefGoogle Scholar
  31. 31.
    Li CY, Schaffler MB, Wolde-Semait HT, Hernandez CJ, Jepsen KJ (2005) Genetic background influences cortical bone response to ovariectomy. J Bone Miner Res 20:2150–2158PubMedCrossRefGoogle Scholar
  32. 32.
    Bouxsein ML, Myers KS, Shultz KL, Donahue LR, Rosen CJ, Beamer WG (2005) Ovariectomy-induced bone loss varies among inbred strains of mice. J Bone Miner Res 20:1085–1092PubMedCrossRefGoogle Scholar
  33. 33.
    Nakamura M, Udagawa N, Matsuura S, Mogi M, Nakamura H, Horiuchi H, Saito N, Hiraoka BY, Kobayashi Y, Takaoka K, Ozawa H, Miyazawa H, Takahashi N (2003) Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144:5441–5449PubMedCrossRefGoogle Scholar
  34. 34.
    Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192:463–474PubMedCrossRefGoogle Scholar
  35. 35.
    Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R (1993) Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690–709PubMedCrossRefGoogle Scholar
  36. 36.
    Hattersley G, Dorey E, Horton MA, Chambers TJ (1998) Human macrophage colony-stimulating factor inhibits bone resorption by osteoclasts disaggregated from rat bone. J Cell Physiol 137:199–203CrossRefGoogle Scholar
  37. 37.
    Robling AG, Turner CH (2002) Mechanotransduction in bone: genetic effects on mechanosensitivity in mice. Bone 31:562–569PubMedCrossRefGoogle Scholar
  38. 38.
    Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK (2003) Bone loss and bone size after menopause. N Engl J Med 349:327–334PubMedCrossRefGoogle Scholar
  39. 39.
    Szulc P, Seeman E, Duboeuf F, Sornay-Rendu E, Delmas PD (2006) Bone fragility: failure of periosteal apposition to compensate for increased endocortical resorption in postmenopausal women. J Bone Miner Res 21:1856–1863PubMedCrossRefGoogle Scholar
  40. 40.
    McCalden RW, McGeough JA, Barker MB, Court-Brown CM (1993) Age-related changes in the tensile properties of cortical bone. The relative importance of changes in porosity, mineralization, and microstructure. J Bone Joint Surg Am 75:1193–1205PubMedGoogle Scholar
  41. 41.
    Bell KL, Loveridge N, Power J, Garrahan N, Meggitt BF, Reeve J (1999) Regional differences in cortical porosity in the fractured femoral neck. Bone 24:57–64PubMedCrossRefGoogle Scholar
  42. 42.
    Morey-Holton ER, Globus RK (2002) Hindlimb unloading rodent model: technical aspects. J Appl Physiol 92:1367–1377PubMedCrossRefGoogle Scholar
  43. 43.
    Simske SJ, Schmeister TA, Fleet ML, Broz JJ, Gayles EC, Luttges MW (1994) An experimental model for combined neural, muscular, and skeletal degeneration. J Neuromusculoskelet System 2:116–123Google Scholar
  44. 44.
    Yuan YY, Kostenuik PJ, Morony S, Simionescu DT, Basalyga DM, Bateman TA (2006) RANKL infusion as a disease model: implications for bone and vascular systems [abstract]. J Bone Miner Res 21:S163CrossRefGoogle Scholar
  45. 45.
    Halloran BP, Ferguson VL, Simske SJ, Burghardt A, Venton LL, Majumdar S (2002) Changes in bone structure and mass with advancing age in the male C57BL/6J mouse. J Bone Miner Res 17:1044–1050PubMedCrossRefGoogle Scholar
  46. 46.
    Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304–309PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • S. A. J. Lloyd
    • 1
  • Y. Y. Yuan
    • 1
  • P. J. Kostenuik
    • 2
  • M. S. Ominsky
    • 2
  • A. G. Lau
    • 1
  • S. Morony
    • 2
  • M. Stolina
    • 2
  • F. J. Asuncion
    • 2
  • Ted A. Bateman
    • 1
  1. 1.Department of BioengineeringClemson UniversityClemsonUSA
  2. 2.Metabolic DisordersAmgen, Inc.Thousand OaksUSA

Personalised recommendations